Pulmonology Perspectives on Biomarker Testing in NSCLC: Multidisciplinary Management in an Era of Rapid Change
1h 47m
·
CEConversations
·
To receive up to 2.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/2022chest-podcast
This dynamic live symposium, led by top experts in the field of pulmonary medicine and NSCLC, will take attendees on a deep dive into the sentinel role of the pulmonologist in the NSCLC management paradigm, exploring adaptive mechanisms to optimize collaborative strategies in a patient centric manner.
Learning Objectives
- Review the sentinel placement of the pulmonologist in the management of NSCLC, including their principal role in diagnostics, disease staging, and molecular testing.
- Evaluate clinical and patient-value driven factors that may help inform nodule evaluation and diagnostic strategies for pulmonologists, thus ensuring “the right tissue in the right amount from the right place for the right patient.”
- Demonstrate knowledge of guideline recommendations and practical considerations for the use of EBUS-TNBA techniques by pulmonologists, emphasizing the fundamentals of safely and effectively obtaining adequate tissue for diagnosis and molecular characterization.
- Describe the evolving role of targeted therapy and immunotherapy in NSCLC and analyze currently FDA-approved therapeutics across the NSCLC disease continuum, highlighting the role of molecular testing for guiding treatment and individualizing patient care.
- Explore the established utility of next-generation sequencing (NGS) and discuss the potential for emerging “next-generation” biomarkers in the NSCLC management paradigm.
- Apply patient-centric, evidence-supported collaborative care strategies to real-world, case-based scenarios in order to elucidate the pivotal role of the pulmonologist on the multidisciplinary team across the NSCLC continuum of care.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from AstraZeneca.
The episode Pulmonology Perspectives on Biomarker Testing in NSCLC: Multidisciplinary Management in an Era of Rapid Change from the podcast CEConversations has a duration of
1:47:28. It was first published
More episodes from CEConversations
Cancer-Associated VTE: Balancing Risk and Reward with Modern Anticoagulation
Reducing barriers to adequate anticoagulation for patients with cancer improves outcomes for those with cancer-associated venous thromboembolisms (CA-VTEs). Advances in cancer treatments and the resulting improvements in patient survival have led to an increase in the number of patients with cancer who develop a VTE at some point during their treatment (around 15%). CA-VTE is associated with decreased survival, increased morbidity and hospitalization, and the potential delay or interruption of systemic anti-cancer therapy. During this series, our faculty will expand clinician knowledge of VTE risk factors and management strategies, discuss optimal anticoagulation therapy selection and guideline adherence, and explore approaches to working with multidisciplinary teams.
In this 60-minute program, expert faculty will review CA-VTE risk factors and management strategies, discuss optimal anticoagulation therapy selection and guideline adherence, and explore approaches to working with multidisciplinary teams. Clinicians can expect to gain valuable insight that will help them understand and overcome barriers to adequate anticoagulant therapy for patients with cancer.
Actionable Strategies in Community Oncology to Achieve Equity in Triple-Negative Breast Cancer
This podcast focuses on educating, informing, and empowering clinicians involved in the care of patients with triple-negative breast cancer (TNBC) to positively impact the racial/ethnic disparities that negatively impact Black women. Our faculty will explore strategies that promote equitable care and outcomes for all patients; evaluate the role of antibody-drug conjugates (ADCs) in TNBC; and discuss the rapidly evolving clinical practice guidelines, safety and efficacy data of novel therapies, and practical ADC management strategies to anticipate and mitigate adverse events. To claim credit, visit: https://www.ceconcepts.com/activity/actionable-strategies-in-community-oncology-to-achieve-equity-in-triple-negative-breast-cancer-3/
Primary Care Perspectives on Obesity: Embracing Novel Agents to Optimize Patient Outcomes
To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/activity/primary-care-perspectives-on-obesity-embracing-novel-agents-to-optimize-patient-outcomes-2/
This podcast reviews the etiology and epidemiology of obesity, as well as prominent unmet needs and barriers to treatment optimization as a means of providing foundational context for learners. Expert faculty will then lead attendees on an immersive, deep dive through the established paradigm and the preponderance of emerging data for novel weight-loss therapeutics, most notably the GLP-1 agonists and the GLP-1/GIP agonists. The session will conclude with a case-based segment, in which attendees will get to apply the principles they have learned to real-world clinical scenarios, address practical weight-loss challenges, and highlight the instrumental role of the primary care physician as a gatekeeper for the obesity management team. Request credit here: https://www.ceconcepts.com/activity/primary-care-perspectives-on-obesity-embracing-novel-agents-to-optimize-patient-outcomes-2/
Supported through an independent educational grant from Lilly.
Meeting Complex Challenges in Proteinuric Glomerular Disease: An Expert Review of Emerging Data and Novel Therapeutics for IgA Nephropathy
To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/igan-ee-podcast
This activity will take learners on a deep dive into the pathophysiology of proteinuric glomerular disease, with an incisive focus on IgA nephropathy (IgAN). Expert faculty will review the totality of emerging evidence for novel therapeutics in IgAN, including an appraisal of consensus guidelines and regulatory updates. Finally, the session will conclude with a case-based segment wherein attendees will get to apply the principles they’ve learned to real-world clinical scenarios.
Supported through an independent educational grant from Travere.
Bridging Chasms in Bladder Cancer Care: An Expert Case-based Review of Treatment Selection and Sequencing in an Era of Therapeutic Novelty
This educational session will comprehensively evaluate the current state of the bladder cancer management paradigm and investigate the emergence of new data across the totality of the disease continuum, with a particular emphasis on evidence-based treatment sequencing and the role of antibody-drug conjugates (ADCs) in subsequent lines of therapy for advanced disease. To conclude the session, activity attendees will get to apply the therapeutic principles they’ve learned to real-world clinical scenarios which will focus on patient-centric treatment selection and sequencing, as well as recognition, mitigation, and management of treatment-related adverse events.
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation
Collect credit: https://www.ceconcepts.com/gu-cancer23-podcast